GCM
BSX icon

Genus Capital Management’s Boston Scientific BSX Stock Holding History

Genus Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-135,092
Closed -$12.1M – 218
2024
Q4 		$12.1M Buy
135,092
+17,062
+14% +$1.5M 1.64% 14
2024
Q3 		$9.89M Buy
+118,030
New +$9.3M 1.3% 26

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Genus Capital Management's BSX Position: Q1 2026 in Review

Genus Capital Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 3,325 shares — an estimated $317K sold.

Genus Capital Management first reported a position in BSX in Q1 2025 and held it in 4 quarters. The position peaked at $8.46M in Q1 2025. 1,665 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Genus Capital Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
  • Genus Capital Management sold 3,325 Boston Scientific shares in Q1 2026, an estimated $317K.
  • Genus Capital Management first reported a position in Boston Scientific in Q1 2025 and held it in 4 quarters.
  • Genus Capital Management's Boston Scientific position peaked at $8.46M in Q1 2025.
  • 1,665 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Genus Capital Management's 13F filing for Q1 2026, filed 4 May 2026.